Data Supplement from Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial
Year: 2023
Type: other
Abstract: Supplementary Figure 1: Heatmap of the 68 non-small cell lung cancer cell lines with EGFR wild-type used to train the Sorafenib Sensitivity Signature; Supplementary Figure 2: Heatmap of the 37 patients with EGFR mutant tumors using the Sorafenib Sensitivity signature; yes: disease control at 8 weeks; no: no disease control at 8 weeks.
Authors: George R. Blumenschein, Pierre Saintigny, Suyu Liu, Edward S. Kim, Anne S. Tsao, Roy S. Herbst, Christine Alden, J. Jack Lee, Ximing Tang, David J. Stewart, Merrill S. Kies, Frank V. Fossella, Hai T. Tran, L. Mao, Marshall E. Hicks, Jeremy Erasmus, Sanjay Gupta, Luc Girard, Michael Peyton, Lixia Diao, Jing Wang, Suzanne E. Davis, John D. Minna, Ignacio Wistuba, Waun K. Hong, John V. Heymach, Scott M. Lippman
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362429303